UPDATE: Piper Sandler Upgrades Altria To Overweight, Raises Target From $52 To $57 Notes 'JUUL headwinds, FDA/FTC risk had been a concern, but now de-risked'; Firm Remains 'confident in iQOS as a medium- and long-term growth driver'